@SynconaLtd

Creating, Building and Scaling a portfolio of global leaders in life science

 London, England
synconaltd.com/
Joined February 2019
  • Tweets294
  • Following154
  • Followers655
22Media
This week we were pleased to announce the official opening of our new office at 8 Bloomsbury Street by Baroness Manningham-Buller, Chair of the Wellcome Trust #Syncona
1
6
Today Syncona today announced its Third Quarter Update covering the period from 01 October to 31 December 2024. To see the full release, please click here: londonstockexchange.com/news…
1
2
163
Today Syncona announced its Half Year Results. Management will be delivering a presentation followed by a Q&A session which begins at 9am this morning. To register for the webcast, and to see the full release, please click the link below: synconaltd.com/investors/res…
176
Today we announced our first quarter update, highlighting strong clinical execution from a rebalanced and diversified portfolio that continues to attract significant external capital. Read the full announcement here: londonstockexchange.com/news…
1
182
Today Syncona announces its Annual Results for the 12-month period ending 31 March 2024. Management will be delivering a presentation followed by a question and answer session which begins at 9am this morning. To register, and to see the full release: synconaltd.com/investors/res…
2
246
Syncona was pleased to recently welcome two senior leaders to the business in, Executive Partner, John Tsai, and Managing Partner, Roel Bulthuis. Here they discuss their experience, what attracted them to Syncona, and their priorities since joining. synconaltd.com/news-and-insi…

Expansion of our senior team

synconaltd.com
1
225
Autolus Therapeutics announced it has submitted its Biologics License Application to the US #FDA for obe-cel for patients with relapsed/refractory adult B-Cell Acute Lymphoblastic #Leukaemia. Read the full announcement here: synconaltd.com/news-and-insi… #biotech #celltherapy
5
260
Syncona is pleased to announce its Interim Results for the 6-month period ending 30 September 2023. To read the full announcement, please visit the following link: synconaltd.com/investors/res…
1
241
We’ve released our Q1 update, highlighting the continued progress across our maturing portfolio. Our portfolio companies continue to deliver on their clinical and operational plans as our late-stage clinical companies approach important milestones: tinyurl.com/59u7ef3e
1
2
267
“Simply being the first mover against a given target won’t be enough”, Syncona CEO Chris Hollowood shares his perspective on the future of the scientific landscape. Find out more about current opportunities in the blog: synconaltd.com/news-and-insi… #lifescience #pharma #blog
1
200
Strategy Director at Syncona portfolio company OMass Therapeutics @omasstx, Miguel Campos Silva, speaks about OMass’ #sustainability journey and Syncona’s active involvement. Read the full Q&A with Miguel here: synconaltd.com/news-and-insi… #lifescience
1
4
322
Today @FreelineLife announced it has dosed its first patient with its novel adeno-associated virus (#AAV) #genetherapy candidate for #Gaucher disease, marking an important step forward for the Gaucher community. Read the full announcement here: synconaltd.com/news-and-insi…
2
161
Today Syncona announces its Preliminary Results for the 12-month period ending 31 March 2023. Management will be delivering a presentation followed by a Q&A session which begins at 9am. To register for the webcast, and to see the full release, click below: bit.ly/440xXot
1
185
This week not only did we launch our new brand but we launched Beacon Therapeutics, a new leading ophthalmic gene therapy company. Watch the full video on Beacon’s launch here: synconaltd.com/news-and-insi… #ophthalmology
162
Following today’s launch of Beacon Therapeutics, a new leading ophthalmic gene therapy company, please visit our new refreshed website to find out more about the company. Watch the full video on Beacon’s launch here: synconaltd.com/news-and-insi…
1
188
We’re excited to launch a leading ophthalmic gene therapy company Beacon Therapeutics with £96 million Series A financing by combining AGTC’s late-stage X-linked retinitis pigmentosa (XLRP) programme with two proprietary pre-clinical programmes. More here: synconaltd.com/news-and-insi…

Beacon Therapeutics launches with £96 million ($120 million) to develop a new generation of gene...

synconaltd.com
1
2
4
281
Syncona is pleased to announce that its portfolio company Quell has entered into a collaboration, exclusive option and license agreement with @AstraZeneca, in which Quell will receive $85 million upfront from AstraZeneca. Read more here: bit.ly/3P1EQSa
3
173
Syncona CEO Chris Hollowood has been quoted in today's @thetimes, having spoken to @alexralph about the opportunities and challenges facing biotechs in the UK. bit.ly/3MG6J1c #UKbiotech #opportunities
138
#ICYMI the sale of Silicon Valley Bank UK @SVB_UK to @HSBC over the weekend will safeguard thousands of British jobs, at no cost to the taxpayer. Here's how government, the tech and life sciences sectors worked together to deliver the best possible outcome for the UK economy.

Government facilitates purchase of Silicon Valley Bank UK by HSBC

Find out how government and the Bank of England facilitated the purchase of Silicon Valley Bank UK by HSBC and saved thousands of UK tech companies.

43
13
5
59
13,089
Read Syncona CEO Chris Hollowood reflect on the current state of the biotech sector and what's next for Syncona: bit.ly/3J5zORb
1
161
Today is @rarediseaseday. Read how @omasstx, is using new technologies to develop treatments for rare immunological and genetic diseases. 🔬 ox.ac.uk/research/research-i… @OxSciences @SynconaLtd @innovateuk @OxfordChemistry @WolfsonCollege #OxfordImpacts #SDG3
Artistic impression of a plasma membrane of a human cell. Photo credit: Shutterstock

ALT Artistic impression of a plasma membrane of a human cell. Photo credit: Shutterstock

3
1
326
Load more